# OFSET (NCT05879926)

> Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05879926
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: NRG Oncology
- Conditions: Breast Cancer
- Interventions: Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression
- Enrollment: 3960
- Primary outcome: Invasive breast cancer-free survival (IBCFS)

## Commentary we found

- X threads: 12
- YouTube: 9
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ofset-nct05879926

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05879926", "email": "<work email>"}; the inbox owner confirms by the emailed link.